Sunday, August 5th
|
| 2:00 PM - 8 PM | Arrival & Registration |
| 4:30 PM - 6 PM | Welcoming Mixer |
| 6:00 PM - 7:00 PM | Dinner |
|
|
| Sunday Evening Session | Topics in Drug Safety |
|
| Discussion Leader: Joel Barrish (BMS) |
|
|
| 7:15 PM - 7:30 PM | Introduction and Conference Welcome |
| 7:30 PM - 8:00 PM | Kathleen Uhl (FDA)
Drug Safety in the 21st Century: An FDA Perspective |
| 8:00 PM - 8:10 PM | Discussion |
| 8:10 PM - 8:40 PM | Kenneth Thummel (U. Washington)
Drug-Drug Interactions: Quantitative Predictions and Clinical Significance |
| 8:40 PM - 8:50 PM | Discussion |
| 8:50 PM - 9:20 PM | Robert Gerwien (Curagen)
Strategies of Toxicogenomic Data Analysis |
| 9:20 PM - 9:30 PM | Discussion |
| 9:30 PM - 10:00 PM | Stephen Durham (BMS)
Predictive Toxicology: The Early Identification of Drug Safety Liabilities |
| 10:05 PM - 10:10 PM | Discussion |
| 10:10 PM | Continuation of Welcoming Mixer |
|
|
Monday, August 6th
|
| 7:00 AM - 8:30 AM | Breakfast |
|
|
| Monday Morning Session | Quality of Life Drugs |
|
| Discussion Leader: Steve Street (Pfizer) |
|
|
| 8:45 AM - 9:00 AM | Greeting and Meeting Business |
| 9:00 AM - 9:30 AM | Don Middleton (Pfizer)
The Design and Profile of Peripherally Restricted Delta Opioid Agonists for the Treatment of Irritable Bowel Syndrome |
| 9:30 AM - 9:40 AM | Discussion |
| 9:40 AM - 10:10 AM | Guixue Yu (BMS)
Novel PDE5 Inhibitors with Greater Potency and Selectivity than Sildenafil, for treatment of Male Erectile Dysfunction |
| 10:10 AM - 10:20 AM | Discussion |
| 10:20 AM - 10:50 AM | Photograph and Break |
| 10:50 AM -11:20 AM | Bob Mook (Glaxo Smith-Kline)
Discovery of GG745, a 5-a Reductase Inhibitor for Treatment of BPH |
| 11:20 AM - 11:30 AM | Discussion |
| 11:30 AM - 12:00 PM | Kristof Van Emelen (Janssen)
Design of Fundus-Relaxing Compounds for Treatment of Functional Dyspepsia |
| 12:00 PM - 12:10 PM | Discussion |
|
|
| 12:30 PM - 1:30 PM | Lunch |
| 12:10 PM - 6:00 PM | FREE TIME (organized Mt. Kearsearge hike available) |
| 6:00 PM - 7:00 PM | Dinner |
|
|
| Monday Evening Session | New Approaches to Treating Obesity |
|
| Discussion Leader: Karin Briner (Lilly) |
|
|
| 7:30 PM - 8:00 PM | Atonio Tataranni (NIDDK Laboratories)
New Targets for Obesity Research |
| 8:00 PM - 8:10 PM | Discussion |
| 8:10 PM - 8:40 PM | Dennis Heyer (Glaxo Smith-Kline)
NPY5 Antagonists for Obesity |
| 8:40 PM - 8:50 PM | Discussion |
| 8:50 PM - 9:20 PM | Al Robichaud (Dupont)
A Novel Approach to the Treatment of Obesity. The Design and Synthesis of Orally Bioavailable, Selective 5-HT2C Agonists |
| 9:20 PM - 9:30 PM | Discussion |
| 9:30 PM - 10:00 PM | Brad Morgan (Pfizer)
Selective Glucocorticoid Receptor Modulators |
| 10:00 PM - 10:10 PM | Discussion |
| |
|
|
Tuesday, August 7th
|
| 7:00 AM - 8:30 AM | Breakfast |
|
|
| Tuesday Morning Session | New Approaches to Treating Atherosclerosis |
|
| Discussion Leader: Christine Tarby (DuPont) |
|
|
| 9:00 AM - 9:30 AM | Mark Kowala (BMS)
Beyond Traditional Cardiovascular Risk Factors - Treating Atherosclerosis as a Chronic Inflammatory Disease |
| 9:30 AM - 9:40 AM | Discussion |
| 9:40 AM - 10:10 AM | Colin Leach (Glaxo Smith-Kline)
Lp-PLA2 inhibitors - Novel, non lipid lowering drugs for atherosclerosis |
| 10:10 AM - 10:20 AM | Discussion |
| 10:20 AM - 10:50 AM | Break |
| 10:50 AM -11:20 AM | Huw Davies (AstraZeneca)
Identification of novel CCR2b antagonists for the treatment of inflammatory conditions including atherosclerosis |
| 11:20 AM - 11:30 AM | Discussion |
| 11:30 AM - 12:00 PM | Jon L. Collins
(Glaxo Smith-Kline)
LXR Agonists and Atherosclerosis |
| 12:00 PM - 12:10 PM | Discussion |
|
|
| 12:30 PM - 1:30 PM | Lunch |
| 12:10 PM - 5:00 PM | FREE TIME (organized annual East/West Softball game) |
| 5:00 PM - 6:00 PM | POSTER SESSION #1 (Discussion Leader: John Mallamo [Cephalon]) |
| 6:00 PM - 7:00 PM | Dinner |
|
|
| Tuesday Evening Session | New Approaches for the Prevention/ Treatment of Osteoporosis |
|
| Discussion Leader: Mark Duggan (Merck) |
|
|
| 7:30 PM - 8:00 PM | Sevgi Rodan (Merck)
New Molecular Targets for Inhibition of Bone Resorption |
| 8:00 PM - 8:10 PM | Discussion |
| 8:10 PM - 8:40 PM | Robert Marquis (Glaxo Smith-Kline)
Inhibition of the Cysteine Protease Cathepsin K |
| 8:40 PM - 8:50 PM | Discussion |
| 8:50 PM - 9:20 PM | Eva Altmann (Novartis)
N-Acyl-a-amino acid-(arylaminoethyl)amides Represent a New Class of Selective Non-covalent Inhibitors of Cathepsin K |
| 9:20 PM - 9:30 PM | Discussion |
| 9:30 PM - 10:00 PM | Robert Meissner (Merck)
Tetrahydronaphthyridine-Containing Antagonists of the Integrin avb3 |
| 10:00 PM - 10:10 PM | Discussion |
|
|
Wednesday, August 8th
|
| 7:00 AM - 8:30 AM | Breakfast |
|
|
| Wednesday Morning Session | New Approaches to Treating Microbial Infections |
|
| Discussion Leader: Joanne Bronson (BMS) |
|
|
| 9:00 AM - 9:30 AM | David Payne (Glaxo Smith-Kline)
The Impact of Genomics on Antibacterial Discovery |
| 9:30 AM - 9:40 AM | Discussion |
| 9:40 AM - 10:10 AM | Michael Barbachyn (Pharmacia Upjohn)
Recent Developments with Oxazolidinone Antibacterial Agents |
| 10:10 AM - 10:20 AM | Discussion |
| 10:20 AM - 10:50 AM | Election of Vice-Chair Elect and Break |
| 10:50 AM - 11:20 AM | Thomas Renau (Microcide Pharmaceuticals)
Developing Inhibitors of Efflux Pumps in Pseudomonas aeruginosa: Program Challenges and SAR |
| 11:20 AM - 11:30 AM | Discussion |
| 11:30 AM - 12:00 PM | Marvin Miller (University of Notre Dame)
Design, Synthesis, and Study of New Antimicrobial Agents and Drug Delivery Systems |
| 12:00 PM - 12:10 PM | Discussion |
|
|
| 12:30 PM - 1:30 PM | Lunch |
| 12:10 PM - 5:00 PM | FREE TIME (organized annual Vice-Chair Elect Golf Tournament) |
| 5:00 PM - 6:00 PM | POSTER SESSION #2 (Discussion Leader: John Mallamo [Cephalon]) |
| 6:00 PM - 7:00 PM | Dinner |
|
|
| Wednesday Evening Session | Drugs Modulating Kinases and Phosphatase |
|
| Discussion Leader: Celia Dominguez (Amgen) |
|
|
| 7:30 PM - 8:00 PM | Rick Kendall (Amgen): Biological Overview of Kinases and Phosphatases |
| 8:00 PM - 8:10 PM | Discussion |
| 8:10 PM - 8:40 PM | Henrik Sune Andersen (Novo Nordisk)
PTP1B (diabetes, inflammation) |
| 8:40 PM - 8:50 PM | Discussion |
| 8:50 PM - 9:20 PM | Paul Manley (Novartis)
GLIVEC (STI571): A tyrosine kinase inhibitor tailored for leukemia therapy |
| 9:20 PM - 9:30 PM | Discussion |
| 9:30 PM - 10:00 PM | Allan Wagman (Chiron)
GSK3 |
| 10:00 PM - 10:10 PM | Discussion |
|
|
Thursday, August 9th
|
| 7:00 AM - 8:30 AM | Breakfast |
|
|
| Thursday Morning Session | Special Topics |
|
| Discussion Leader: John Lowe (Pfizer) |
|
|
| 9:00 AM - 9:30 AM | George Chang (Pfizer)
Discovery of a potent, orally active and clinically efficacious MTP inhibitor via a high-speed synthesis paradigm |
| 9:30 AM - 9:40 AM | Discussion |
| 9:40 AM - 10:10 AM | Paul Ornstein (Lilly)
The discovery of potent, selective mGluR5 antagonists and their activity as anti-migraine agents |
| 10:10 AM - 10:20 AM | Discussion |
| 10:20 AM - 10:50 AM | Break |
| 10:50 AM -11:20 AM | George Muller (Celgene)
Clinical activity of novel PDE4 inhibitors |
| 11:20 AM - 11:30 AM | Discussion |
| 11:30 AM - 12:00 PM | Iyassu Sebhat (Merck)
The erectogenic activity of small molecule MC4-R agonists |
| 12:00 PM - 12:10 PM | Discussion |
|
|
| 12:30 PM - 1:30 PM | Lunch |
| 5:00 PM - 6:00 PM | Chairman's Social/Mixer |
| 6:00 PM - 7:00 PM | Dinner |
|
|
| Thursday Evening Session | New Drugs for Treating Alzheimer's Disease |
|
| Discussion Leader: Donna Huyrn (Wyeth-Ayerst) |
|
|
| 7:30 PM - 8:00 PM | Steve Jacobsen (Wyeth-Ayerst)
Approaches to Alzheimer's Disease |
| 8:00 PM - 8:10 PM | Discussion |
| 8:10 PM - 8:40 PM | James Audia (Lilly)
Inhibitors of APP Processing |
| 8:40 PM - 8:50 PM | Discussion |
| 8:50 PM - 9:20 PM | Mark Findeis (Praecis Pharmaceuticals)
Inhibitors of b-amyloid Aggregation |
| 9:20 PM - 9:30 PM | Discussion |
|
|
END OF SCIENTIFIC SESSION |
|
|
Friday, August 10th
|
| 7:00 AM - 8:30 AM | Breakfast |
| 9:00 AM | Bus Departs for Logan Airport |
